0.39%
3.52%
-10.61%
3.01%
21.51%
35.62%
127.69%
AI Spotlight on SFZN
Company Description
Siegfried Holding AG engages in the life sciences business worldwide.The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products.It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production.
In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases.Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products.The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Market Data
| Last Price | 1028 |
| Change Percentage | 0.39% |
| Open | 1028 |
| Previous Close | 1024 |
| Market Cap ( Millions) | 4409 |
| Volume | 7695 |
| Year High | 1188 |
| Year Low | 831.5 |
| M A 50 | 1024.12 |
| M A 200 | 1022.9 |
Financial Ratios
| FCF Yield | 2.47% |
| Dividend Yield | 0.35% |
| ROE | 15.13% |
| Debt / Equity | 49.61% |
| Net Debt / EBIDTA | 143.78% |
| Price To Book | 5.09 |
| Price Earnings Ratio | 34.2 |
| Price To FCF | 40.41 |
| Price To sales | 3.43 |
| EV / EBITDA | 18.78 |
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Drug Substances
Expected Growth : 5 %
What the company do ?
Drug Substances from Siegfried Holding AG refers to the active pharmaceutical ingredients (APIs) manufactured by the company, used to produce medicinal products.
Why we expect these perspectives ?
Siegfried Holding AG's Drug Substances segment growth is driven by increasing demand for complex APIs, strategic partnerships, and capacity expansions. The company's expertise in HPAPIs and ADCs, coupled with a strong pipeline of new projects, contributes to its growth. Additionally, the rising need for outsourcing in the pharmaceutical industry and Siegfried's ability to provide integrated services also support its growth momentum.
Segment n°2 -> Drug Products
Expected Growth : 7 %
What the company do ?
Siegfried Holding AG's drug products include active pharmaceutical ingredients and finished dosage forms for various therapeutic areas, manufactured and supplied to pharmaceutical companies.
Why we expect these perspectives ?
Siegfried Holding AG's 7% growth in drug products is driven by increasing demand for contract manufacturing services, expansion into emerging markets, and strategic partnerships. Additionally, investments in capacity expansion, process optimization, and quality enhancements have improved operational efficiency, contributing to revenue growth.
Siegfried Holding Ag Products
| Product Range | What is it ? |
|---|---|
| Active Pharmaceutical Ingredients (APIs) | Siegfried Holding AG develops and manufactures high-quality Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry. |
| Contract Manufacturing | Siegfried Holding AG offers contract manufacturing services for pharmaceutical and biotech companies, providing customized solutions for drug development and production. |
| Pharmaceutical Intermediates | Siegfried Holding AG develops and manufactures pharmaceutical intermediates, which are used as building blocks for the production of APIs. |
| Custom Synthesis | Siegfried Holding AG provides custom synthesis services, developing and manufacturing complex molecules for pharmaceutical and biotech companies. |
| Analytical Services | Siegfried Holding AG offers analytical services, providing testing and characterization of pharmaceutical products and APIs. |
Siegfried Holding AG's Porter Forces
Threat Of Substitutes
The threat of substitutes for Siegfried Holding AG is moderate, as there are some alternatives available in the market, but they are not very attractive to customers.
Bargaining Power Of Customers
The bargaining power of customers for Siegfried Holding AG is low, as customers have limited options and the company has a strong brand presence.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Siegfried Holding AG is moderate, as the company has some negotiating power, but suppliers also have some bargaining power.
Threat Of New Entrants
The threat of new entrants for Siegfried Holding AG is high, as the industry is attractive and there are low barriers to entry.
Intensity Of Rivalry
The intensity of rivalry for Siegfried Holding AG is high, as the industry is highly competitive and there are many players competing for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 36.33% |
| Debt Cost | 3.95% |
| Equity Weight | 63.67% |
| Equity Cost | 7.15% |
| WACC | 5.98% |
| Leverage | 57.05% |
Siegfried Holding AG : Quality Control
Siegfried Holding AG passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IPN.PA | Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors … |
| ALM.MC | Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for … |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North … |
| HIK.L | Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage … |
| ALVO | Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ipsen
A-Score
1-Year Total Return ->
🥈
Hikma Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
Almirall
A-Score
1-Year Total Return ->
4
Siegfried Holding
A-Score
1-Year Total Return ->
5
Sobi
A-Score
1-Year Total Return ->
6
